Research Insight
New Study Shows Cialis® Significantly Improved Study Endpoints in Men
Eli Lilly and Company announced that a pivotal Phase III study of Cialis® (tadalafil) tablets 5 mg for once daily use met its co-primary endpoints, significantly improving measures of both erectile dysfunction (ED) and signs and symptoms of benign...
Research Insight
Hybrigenics’ inecalcitol inhibits the growth of human hormone-dependent prostate cancer cells in vitro and in vivo
Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext in Paris, with a focus on research and development of new treatments of proliferative diseases, announces today the online publication of a scientific article by Dr Ryoko Okamoto and co-authors...
Research Insight
New Study Released Showed Patients With Deadly Form of Lung Cancer Lived Longer Without Disease Worsening
Eli Lilly and Company announced that PARAMOUNT, its Phase III study evaluating ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, met its primary endpoint of progression-free survival, or the time a patient is alive without their disease worsening,...
Research Insight
King’s College London Prostate cancer treatment study shows percentage of men who had a radical prostatectomy survived for 15 years
A study co-led by researchers at King’s College London shows that the percentage of men who had a radical prostatectomy (removal of the prostate and surrounding cancer cells) and survived for 15 years is higher than men who were...
Research Insight
Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data from Phase 2 Study of ABT-450/r
Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C (HCV) infection. Study results show that 92 percent (22 of...
Research Insight
Cytheris announces results of phase IIa study indicating that recombinant interleukin-7 (CYT107)
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced results of a multi-center Phase IIa study designed to investigate the potential of Interleukin-7 (CYT107) therapy to reconstitute CD4...
Research Insight
Progenics Reports Positive Preliminary Data from Ongoing Phase 1 Clinical Study of PSMA ADC
Progenics Pharmaceuticals, Inc.reported positive preliminary data from an ongoing phase 1 study of PSMA ADC, an antibody-drug conjugate (ADC) designed to selectively deliver chemotherapy to cells that express prostate-specific membrane antigen (PSMA). Antitumor activity, as reflected by clinical and/or...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read